Mersana Therapeutics, Inc.
MRSN
$7.65
-$0.10-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.14% | -11.21% | 9.88% | -14.70% | -22.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.14% | -11.21% | 9.88% | -14.70% | -22.68% |
| Cost of Revenue | -18.54% | -39.28% | -50.75% | -58.12% | -54.33% |
| Gross Profit | 36.44% | 52.48% | 70.81% | 71.60% | 62.29% |
| SG&A Expenses | -22.18% | -27.66% | -31.46% | -34.50% | -31.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.77% | -35.72% | -45.22% | -51.71% | -48.53% |
| Operating Income | 30.20% | 42.72% | 57.10% | 59.43% | 53.08% |
| Income Before Tax | 29.74% | 45.41% | 59.94% | 62.34% | 51.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.34% | 45.10% | 59.69% | 62.13% | 51.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.34% | 45.10% | 59.69% | 62.13% | 51.31% |
| EBIT | 30.20% | 42.72% | 57.10% | 59.43% | 53.08% |
| EBITDA | 30.42% | 43.17% | 57.68% | 60.01% | 53.62% |
| EPS Basic | 31.01% | 47.20% | 62.32% | 65.61% | 57.80% |
| Normalized Basic EPS | 29.14% | 43.94% | 60.65% | 64.69% | 61.33% |
| EPS Diluted | 31.01% | 47.20% | 62.32% | 65.61% | 57.80% |
| Normalized Diluted EPS | 29.14% | 43.94% | 60.65% | 64.69% | 61.33% |
| Average Basic Shares Outstanding | 2.15% | 3.14% | 5.58% | 9.57% | 14.99% |
| Average Diluted Shares Outstanding | 2.15% | 3.14% | 5.58% | 9.57% | 14.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |